About Aeolus Pharmaceuticals (OTCMKTS:AOLS)
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.
Industry, Sector and Symbol:
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:AOLS
- CUSIP: N/A
- Web: www.aeoluspharma.com
- Current Ratio: 1.31%
- Quick Ratio: 1.31%
Sales & Book Value:
- Annual Sales: $2.08 million
- Price / Sales: 7.31
- Book Value: $0.02 per share
- Price / Book: 5.00
- Trailing EPS: ($0.04)
- Net Income: ($3,550,000.00)
- Net Margins: -531.00%
- Return on Equity: -246.63%
- Return on Assets: -175.14%
- Employees: 4
- Outstanding Shares: 152,090,000
Frequently Asked Questions for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
What is Aeolus Pharmaceuticals' stock symbol?
Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."
How were Aeolus Pharmaceuticals' earnings last quarter?
Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) announced its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company earned $0.01 million during the quarter. Aeolus Pharmaceuticals had a negative net margin of 531.00% and a negative return on equity of 246.63%. View Aeolus Pharmaceuticals' Earnings History.
When will Aeolus Pharmaceuticals make its next earnings announcement?
Who are some of Aeolus Pharmaceuticals' key competitors?
Some companies that are related to Aeolus Pharmaceuticals include Prana Biotechnology Ltd (PRAN), Tandem Diabetes Care (TNDM), Streamline Health Solutions (STRM), Trimel Pharmaceuticals Corp. (TRLPF), Tonix Pharmaceuticals Holding Corp. (TNXP), Orexigen Therapeutics (OREX), Zosano Pharma Corporation (ZSAN), Tokai Pharmaceuticals (NVUS), Cleveland BioLabs (CBLI), HTG Molecular Diagnostics (HTGM), Pain Therapeutics (PTIE), Catalyst Biosciences (CBIO), ReWalk Robotics Ltd (RWLK), Concordia International Corp. (CXRX), Apricus Biosciences (APRI), TrovaGene (TROV), Eleven Biotherapeutics (EBIO) and Cellectar Biosciences (CLRB).
Who are Aeolus Pharmaceuticals' key executives?
Aeolus Pharmaceuticals' management team includes the folowing people:
- David C. Cavalier, Chairman of the Board, Interim Chief Financial Officer (Age 45)
- John L. McManus, President, Chief Executive Officer (Age 50)
- John M. Clerici, Independent Director (Age 44)
- John M. Farah Jr., Ph.D., Independent Director (Age 62)
- Mitchell D. Kaye J.D., Independent Director (Age 46)
- Amit Kumar Ph.D., Independent Director (Age 53)
- Chris A. Rallis, Independent Director (Age 61)
How do I buy Aeolus Pharmaceuticals stock?
Shares of Aeolus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeolus Pharmaceuticals' stock price today?
One share of Aeolus Pharmaceuticals stock can currently be purchased for approximately $0.10.
How big of a company is Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals has a market capitalization of $15.21 million and generates $2.08 million in revenue each year. The biopharmaceutical company earns ($3,550,000.00) in net income (profit) each year or ($0.04) on an earnings per share basis. Aeolus Pharmaceuticals employs 4 workers across the globe.
How can I contact Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]
MarketBeat Community Rating for Aeolus Pharmaceuticals (OTCMKTS AOLS)MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Aeolus Pharmaceuticals (OTCMKTS:AOLS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
Analysts' Ratings History for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
Earnings History by Quarter for Aeolus Pharmaceuticals (OTCMKTS AOLS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/20/2017|| || || || || || || || |
|8/14/2017||Q3 2017||($0.01)||$0.01 million||View||N/A|
|5/15/2017||Q2 2017||($0.01)||$0.13 million||View||N/A|
|2/17/2017||Q1 2017||($0.01)||$0.08 million||View||N/A|
|8/17/2015||Q3 2015||($0.01)||$0.06 million||View||N/A|
|2/13/2015||Q1 2015||($0.01)||$0.93 million||View||N/A|
Earnings Estimates for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aeolus Pharmaceuticals (OTCMKTS AOLS)
Insider Ownership Percentage: 66.60%
Insider Trades by Quarter for Aeolus Pharmaceuticals (OTCMKTS AOLS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/6/2013||John L Mcmanus||CEO||Buy||10,000||$0.35||$3,500.00|| |
Latest Headlines for Aeolus Pharmaceuticals (OTCMKTS AOLS)
Aeolus Pharmaceuticals (OTCMKTS AOLS) Chart for Sunday, November, 19, 2017